AU2022275011A1 - Modulators of sortilin activity - Google Patents

Modulators of sortilin activity Download PDF

Info

Publication number
AU2022275011A1
AU2022275011A1 AU2022275011A AU2022275011A AU2022275011A1 AU 2022275011 A1 AU2022275011 A1 AU 2022275011A1 AU 2022275011 A AU2022275011 A AU 2022275011A AU 2022275011 A AU2022275011 A AU 2022275011A AU 2022275011 A1 AU2022275011 A1 AU 2022275011A1
Authority
AU
Australia
Prior art keywords
propanamido
formamido
hydroxyphenyl
alkyl
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022275011A
Other languages
English (en)
Other versions
AU2022275011A9 (en
Inventor
Manuel Javier Cases-Thomas
Mads Fuglsang KJØLBY
Paul Brian Little
Anders Nykjaer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vesper Bio ApS
Original Assignee
Insusense ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insusense ApS filed Critical Insusense ApS
Publication of AU2022275011A1 publication Critical patent/AU2022275011A1/en
Publication of AU2022275011A9 publication Critical patent/AU2022275011A9/en
Assigned to VESPER BIO APS reassignment VESPER BIO APS Amend patent request/document other than specification (104) Assignors: INSUSENSE ApS
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Sawing (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Secondary Cells (AREA)
  • Pyridine Compounds (AREA)
AU2022275011A 2021-05-14 2022-05-13 Modulators of sortilin activity Abandoned AU2022275011A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21173972.7A EP4089102A1 (en) 2021-05-14 2021-05-14 Modulators of sortilin activity
EP21173972.7 2021-05-14
PCT/EP2022/063049 WO2022238565A2 (en) 2021-05-14 2022-05-13 Compounds

Publications (2)

Publication Number Publication Date
AU2022275011A1 true AU2022275011A1 (en) 2023-11-23
AU2022275011A9 AU2022275011A9 (en) 2023-11-30

Family

ID=75936805

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022275011A Abandoned AU2022275011A1 (en) 2021-05-14 2022-05-13 Modulators of sortilin activity

Country Status (8)

Country Link
US (1) US20240294569A1 (https=)
EP (2) EP4089102A1 (https=)
JP (1) JP2024517498A (https=)
KR (1) KR20240007137A (https=)
CN (1) CN117642416A (https=)
AU (1) AU2022275011A1 (https=)
CA (1) CA3217317A1 (https=)
WO (1) WO2022238565A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4361165A1 (en) * 2022-10-24 2024-05-01 Insusense ApS Modulators of sortilin activity
EP4471047A1 (en) * 2023-05-31 2024-12-04 Insusense ApS Modulators of sortilin activity
JP2026509275A (ja) * 2023-03-07 2026-03-17 ベスパー バイオ アーペーエス ソルチリン修飾剤
EP4428121A1 (en) * 2023-03-07 2024-09-11 Vesper Bio Aps Modulators of sortilin activity
EP4428122A1 (en) * 2023-03-07 2024-09-11 Vesper Bio Aps Sortiline modulators
EP4428124A1 (en) * 2023-03-07 2024-09-11 Vesper Bio Aps Modulators of sortilin activity
EP4719366A1 (en) 2023-05-26 2026-04-08 Bertram Wiedenmann Sortilin inhibitors for treatment of patients with functional neuroendocrine tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW217417B (https=) * 1991-12-04 1993-12-11 Manyu Seiyaku Kk
HUE030465T2 (hu) 2009-05-13 2017-05-29 Antivirális vegyületek
EP2948147B1 (en) * 2013-01-28 2019-03-13 H. Lundbeck A/S N-substituted-5-substituted phthalamic acids as sortilin inhibitors
WO2015131100A1 (en) 2014-02-28 2015-09-03 The Scripps Research Institute Ligand-controlled c(sp3)-h arylation and olefination in synthesis of unnatural chiral alpha amino acids
US20160331746A1 (en) 2015-05-12 2016-11-17 University Of South Florida Sortilin-Binding Small Molecules for Increasing Glucose Uptake
AU2017361155B2 (en) * 2016-11-15 2023-03-30 Tokyo University Of Science Foundation Ras protein degradation inducing molecule and pharmaceutical composition
CN109280075B (zh) * 2017-07-21 2022-05-20 四川海思科制药有限公司 肽酰胺类化合物及其制备方法和在医药上的用途

Also Published As

Publication number Publication date
CN117642416A (zh) 2024-03-01
KR20240007137A (ko) 2024-01-16
US20240294569A1 (en) 2024-09-05
EP4089102A1 (en) 2022-11-16
WO2022238565A3 (en) 2023-02-23
EP4337674A2 (en) 2024-03-20
AU2022275011A9 (en) 2023-11-30
JP2024517498A (ja) 2024-04-22
CA3217317A1 (en) 2022-11-17
WO2022238565A2 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
AU2022275011A9 (en) Modulators of sortilin activity
US20240217922A1 (en) Modulators of sortilin activity
CN103896946A (zh) 用于预防及治疗多种自身免疫疾病的新化合物
WO2023031440A1 (en) 2-amino-5,5-dimethylhexanoic acid derivatives as sortilin modulators for use in the treatment of disease of the central nervous system
US20250161321A1 (en) Amino acid based carbamates and/or ureas for the treatment of sortilin dependent diseases
US20240132514A1 (en) Pyridine derivatives as modulators of sortilin activity
EP4428121A1 (en) Modulators of sortilin activity
EP4428124A1 (en) Modulators of sortilin activity
EP4676915A1 (en) Sortiline modulators

Legal Events

Date Code Title Description
SREP Specification republished
HB Alteration of name in register

Owner name: VESPER BIO APS

Free format text: FORMER NAME(S): INSUSENSE APS